cMRI-BED: A novel informatics framework for cardiac MRI biomarker extraction and discovery applied to pediatric cardiomyopathy classification by Gopalakrishnan, V et al.
RESEARCH Open Access
cMRI-BED: A novel informatics framework for
cardiac MRI biomarker extraction and discovery
applied to pediatric cardiomyopathy classification
Vanathi Gopalakrishnan1,2,3*, Prahlad G Menon4, Shobhit Madan5,6
From 2nd International Work-Conference on Bioinformatics and Biomedical Engineering (IWBBIO 2014)
Grenada, Spain. 7-9 April 2014
* Correspondence: vanathi@pitt.
edu
1Department of Biomedical
Informatics, University of
Pittsburgh, Pittsburgh, PA, USA
Abstract
Background: Pediatric cardiomyopathies are a rare, yet heterogeneous group of
pathologies of the myocardium that are routinely examined clinically using
Cardiovascular Magnetic Resonance Imaging (cMRI). This gold standard powerful non-
invasive tool yields high resolution temporal images that characterize myocardial tissue.
The complexities associated with the annotation of images and extraction of markers,
necessitate the development of efficient workflows to acquire, manage and transform
this data into actionable knowledge for patient care to reduce mortality and morbidity.
Methods: We develop and test a novel informatics framework called cMRI-BED for
biomarker extraction and discovery from such complex pediatric cMRI data that
includes the use of a suite of tools for image processing, marker extraction and
predictive modeling. We applied our workflow to obtain and analyze a dataset of
83 de-identified cases and controls containing cMRI-derived biomarkers for classifying
positive versus negative findings of cardiomyopathy in children. Bayesian rule
learning (BRL) methods were applied to derive understandable models in the form of
propositional rules with posterior probabilities pertaining to their validity. Popular
machine learning methods in the WEKA data mining toolkit were applied using
default parameters to assess cross-validation performance of this dataset using
accuracy and percentage area under ROC curve (AUC) measures.
Results: The best 10-fold cross validation predictive performance obtained on this
cMRI-derived biomarker dataset was 80.72% accuracy and 79.6% AUC by a BRL
decision tree model, which is promising from this type of rare data. Moreover, we
were able to verify that mycocardial delayed enhancement (MDE) status, which is
known to be an important qualitative factor in the classification of cardiomyopathies,
is picked up by our rule models as an important variable for prediction.
Conclusions: Preliminary results show the feasibility of our framework for processing
such data while also yielding actionable predictive classification rules that can
augment knowledge conveyed in cardiac radiology outcome reports. Interactions
between MDE status and other cMRI parameters that are depicted in our rules
warrant further investigation and validation. Predictive rules learned from cMRI data
to classify positive and negative findings of cardiomyopathy can enhance scientific
understanding of the underlying interactions among imaging-derived parameters.
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Background
Cardiovascular Magnetic Resonance Imaging (cMRI) is currently regarded as the gold
standard for the non-invasive acquisition and processing of high-resolution temporal
images for myocardial function and tissue characterization [1]. cMRI is a diagnostic
imaging modality with no ionizing radiation and is available in specialized care clini-
cal centers where it is routinely used to discover sources of abnormalities in cardiac
structure, function and dynamics. Its applicability to the detection and diagnosis of
cardiomyopathies, particularly in pediatric populations, is of immense significance for
timely detection, accurate disease sub-classification and effective clinical management
options with follow-up care by the primary physician in consultation with cardiac
radiologists and specialists. The large amounts of cMRI data acquired per patient
leads to several complexities associated with the annotation of images and extraction
of markers to differentiate the various subtle and rare forms of cardiomyopathies.
These complexities necessitate the development of efficient informatics workflows
among cardiologists, radiologists and primary care physicians to acquire, manage and
transform this data into actionable knowledge for patient care to reduce mortality
and morbidity. Furthermore, there is a clear need to capture, analyse and understand
retrospectively obtained imaging data and the derived parameters to enhance early
detection and timely monitoring of such pediatric heart diseases to lessen morbidities
in adulthood. Cardiomyopathies are believed to be a frequent cause of sudden cardiac
arrest in the young.
Past work in this area has typically been in the image processing domain, wherein
the effort has gone into imaging bio-marker extraction, segmentation of global and
local regions of interest [2], extraction of quantitative metrics such as volume estima-
tion, morphological, functional or flow-based features [3,4] and finally automated tools
for multi-modal image registration. To the best of our knowledge, the clinical work-
flows associated with the cMRI data acquisition and processing have not been studied
from a machine learning perspective to identify areas of inefficiencies wherein intelli-
gent computational tools could be developed to aid pediatric radiologists and cardiolo-
gists in the accurate assessment of cardiomyopathies using a multitude of imaging
biomarkers. In this paper, we develop and test a novel informatics framework called
cMRI-BED (Cardiovascular Magnetic Resonance Imaging Biomarker Extraction and
Discovery) that includes predictive modeling of retrospectively collected, de-identified
cMRI and medical record data to extract classification rules that augment knowledge
obtained from standard practice. We present our preliminary findings from the appli-
cation of this workflow to a dataset containing positive and negative findings for a sub-
set of pediatric patients evaluated for cardiomyopathies.
Cardiovascular disease is the #1 leading cause of death worldwide [5]. Cardiomyopa-
thy (CM) generally refers to a rather rare, yet diverse group of diseases of the heart
muscle that are classified according to anatomy and physiology into the following
types: Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy (DCM), Arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), Restrictive cardiomyo-
pathy (RCM) and unclassified cardiomyopathies (NCM). In 1996, a highly cited
scientific statement from the American Heart Association (AHA) proposed contempor-
ary definitions and classification of primary and secondary cardiomyopathies that took
into account molecular genetics in cardiology [6]. A recent article thoroughly illustrates
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the various types of common and rare cardiomyopathies, and their classification based
on specific morphological and functional phenotypes [7].
cMRI is a popular non-invasive technology for cardiomyopathy evaluation. The basic
protocols for cardiomyopathy assessment using cMRI are discussed and illustrated in
[7]. A further discussion of assessment of rare cardiomyopathies using cMRI is pre-
sented in [8]. Standardized cMRI protocols are reviewed in [9]. cMRI has recently
emerged as a powerful tool for detecting cardiovascular biomarkers [10]. It is helpful
in making a differential diagnosis between different types of primary and secondary
cardiomyopathies [11-13] (see below). In pediatric populations, cardiomyopathies are
of particular significance due to the need for timely intervention to prevent morbid
outcomes.
Cardiomyopathies are of different types, primary and secondary. Genetic cardiomyo-
pathies are of the primary/instrinsic category and include: (i) Hypertrophic cardiomyo-
pathy (HCM or HOCM), (ii) Arrhythmogenic right ventricular cardiomyopathy
(ARVC), (iii) Isolated ventricular non-compaction Mitochondrial myopathy, (iv) Mixed
Dilated cardiomyopathy (DCM), (v) Restrictive cardiomyopathy (RCM), (vi) Acquired
Peripartum cardiomyopathy, (vii) Takotsubo cardiomyopathy and (viii) Loeffler endo-
carditis. Secondary/extrinsic cardiomyopathies can be categorized based on causal rela-
tionships into:
1. Metabolic/storage: Examples are: amyloidosis and hemochromatosis;
2. Inflammatory: Examples are: viral myocarditis and Chagas disease;
3. Endocrine: Examples are: diabetic cardiomyopathy, hyperthyroidism and
acromegaly;
4. Toxicity: Examples are chemotherapy, and alcoholic cardiomyopathy;
5. Neuromuscular: Example: muscular dystrophy;
6. Nutritional diseases: Example: Obesity-associated cardiomyopathy; and
7. Other: “Ischemic cardiomyopathy” is a weakness in the muscle of the heart due to
inadequate oxygen delivery to the myocardium with coronary artery disease being the
most common cause. This aspect is not supported by current cardiomyopathies classi-
fication schemes.
Table 1 depicts statistics on pediatric populations for genetic cardiomyopathies,
which include HCM [14], DCM, ARVC/D, RCM (and iron mediated CM), NCM [15],
along with Tetralogy of Fallot (ToF) [16] that is a morphological congenital heart
disease (CHD) associated with myopathy of the right ventricle. Some examples of
cMRI-based quantitative and qualitative markers are also depicted. These biomarkers
are representative of structure (morphology), function and dynamics (flow) of the heart
muscle. Myocarditis is an inflammatory disease of the myocardium with a wide range
of clinical presentations, from subtle to devastating [17]. We know from literature that
myocarditis falls under the classification of secondary cardiomyopathies of the inflam-
matory subtype. The definition of myocarditis varies, but the central feature is an
infection of the heart, with an inflammatory infiltrate, and damage to the heart muscle,
without the blockage of coronary arteries that define a heart attack (myocardial infarc-
tion) or other common noninfectious causes. Myocarditis may or may not include
death (necrosis) of myocardial tissue. It may include dilated cardiomyopathy. In this
dataset collected and analyzed in this paper, we include patients who were diagnosed
with myocarditis in addition to the primary genetic cardiomyopathies. Myocardial
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delayed enhancement (MDE) is a feature that is very often present in such patients and
we were looking to see if our predictive models pick up this feature for cardiomyopa-
thy classification from cMRI data.
Machine learning methods are now routinely applied to predictive modeling of dis-
ease states from high-dimensional biomedical data, with rule learning methods becom-
ing useful for classification and extraction of discriminatory biomarkers [18,19]. Both
linear and non-linear modeling methods are available for classification tasks, wherein a
classifier is learned using training data containing possible predictors (e.g. biomarkers)
of a target class (e.g. the presence or absence of a disease). A particular method that
has been applied successfully to ‘omic’ biomarker discovery is the Bayesian rule learn-
ing (BRL) [20] system, which uses a Bayesian score to construct Bayesian networks
(BNs) and to learn probabilistic rule models from them. The models produced are
easily interpretable by the biomedical scientist and have been shown to have fewer
markers and equivalent or greater classification performance in comparison to models
derived from other rule learning methods [20,21]. In this paper, we develop and apply
a novel workflow that permits the application of BRL to cMRI-derived biomarkers for
classification of positive versus negative findings of cardiomyopathy in pediatric
patients. The major enhancements in this journal version of our previously published
conference paper [22] are: (a) we have almost doubled the amount of retrospectively
obtained cMRI-derived data which led to reportable and promising cross-validation
Table 1. Incidence, prevelance and other statistics for five cardiomyopathies and a more
prevalent pediatric congential heart disease called Tetralogy of Fallot or ToF, with
associated right ventricular abnormalities
CM Subtypes HCM DCM ARVC/
D
NCM RCM & Iron
mediated CM
ToF16
Incidence (I) OR
Prevalence (P)
P = 1:500 in absence of
aortic valve disease or
systemic hypertension
I = 5-8
cases
/100,000
P = 36
cases
/100,000
I = 1/
10,000
I =
0.05%
to
0.24%
I = 11.4% to 15.1%
in Thalassemia
major patients
Transfusion
Dependent
I = 9/
1000
live
births
#Patients
evaluated for CM
46 129 44 31 35 684
Total number of
positive diagnosis
w/ CMRI CM
11 18 4 15 12 119
cMRI-based QUANTITATIVE markers
LV myocardial wall
thickness
ABNL ABNL NL ABNL ABNL NL
LV mass index ABNL ABNL NL ABNL ABNL NL
LV Volume index ABNL ABNL NL ABNL ABNL ABNL
RV Volume index NL ABNL ABNL NL ABNL ABNL
cMRI-based QUALITATIVE markers
Myocardial
Delayed
Enhancement
+/- +/- +/- +/- +/- +
Wall motion
abnormalities
+/- +/- +/- +/- +/- +/-
Some examples of standard quantitative and qualitative markers from cMRI that are associated with observed normal
(NL) or abnormal (ABNL) values in each disease based on patients seen at the Children’s Hospital of Pittsburgh (CHP)
between 2000 and 2013. LV refers to Left Ventricular and RV to Right Ventricular regions. The qualitative variables
shown in the table are assigned values of + or - indicating that some patients for the particular subtype indicated
presence or absence of that abnormality.
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predictive performance; and (b) included a known qualitative variable (Myocardial
Delayed Enhancement status) to verify predictive rules obtained from BRL.
The main hypothesis is that our novel cMRI-BED framework developed below, which
includes predictive modeling of retrospectively obtained de-identified cMRI-derived
biomarkers and medical record data into the current standard clinical workflows for
evaluating pediatric patients for cardiomyopathy using cardiac MRI will lead to:
(a) better scientific understanding of the interactions among image-derived biomarkers
that impact positive or negative findings, as depicted in easy to understand IF-THEN
propositional rules; and (b) provide additional statistical information to the cardiologist
in terms of the prediction of positive or negative findings based on the predictive
model/rules learned from training data for a new test case. The use of our Bayesian
Rule Learning (BRL) methods provide a posterior probability for each rule, and since
the rules are mutually exclusive, only one rule will be used for providing the predic-
tion. These predictive IF <condition> -THEN <class> rules directly show the non-lin-
ear interactions among the various image-derived biomarkers along with statistical
information which are believed to depict proof of concept for our working hypothesis.
Methods
Figure 1 depicts the cMRI-BED informatics workflow which represents a simplified
process description by which cMRI-derived biomarkers can be extracted and interac-
tions among the biomarkers can be assessed using state-of-the-art predictive rule mod-
els to assist in the accurate classification of cardiomyopathies in children. The
pediatric patient with a suspicion of cardiac disease based on presenting signs and
symptoms is usually referred by the primary care physician (PCP) to consult with
pediatric cardiology for basic initial clinical cardiac evaluation. Accurate evaluation of
Figure 1 Overview of the Cardiovascular Magnetic Resonance Imaging Biomarker Extraction and
Discovery (cMRI-BED) framework. Standard clinical practice is depicted as dotted box.
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complicated cases necessitate advanced cardiac MRI sequences as recommended by the
experienced pediatric radiologist based on initial clinical findings, family history of
patient and published literature and guidelines laid down by the Society for Pediatric
Radiology. These sequences dictate the preparation of the patient, and subsequent
image acquisition by the technician who works together with the radiologist and tech-
nology to capture the appropriate sets of images, ensuring their quality. Phantom runs
are made with a body of water placed in lieu of the patient with the same parameter
settings to ensure that the values obtained by the technology are within acceptable
ranges.
Once the images are acquired, which takes approximately two hours depending on
the cMRI protocol, they are post-processed by the cardiac radiologist, an appropriately
trained physician who can evaluate the large sets of images and mark regions and con-
tours for biomarker quantification looking for context-dependent abnormalities. The
radiologist also provides qualitative assessments for several standard markers. Com-
mercially available image processing software technology is used to assist the radiolo-
gist in performing these assessments, and is made available through the same or other
commercially available vendors at the scanning site. The commercially available soft-
ware technology permits the generation of standard reports that contain quantitative
and qualitative assessments of the cMRI-based diagnosis, and these reports are sent to
the referring pediatric cardiologist for appropriate treatment. Within the cMRI-BED, we
propose to include our novel predictive modeling tools [20] to analyze retrospective data
acquired for case/control discrimination from the hospital’s database for performing
hypothesis driven retrospective and prospective clinical research studies (see Table 1 for
availability of subjects for different CM types). We will generate classification rules that
can inform the cardiac radiologist, referring pediatric cardiologist and the PCP about the
kinds of interactions between different markers that can better discriminate CM sub-
types for appropriate management based on a training dataset, and we will also be able
to give a diagnosis/prediction for a given patient which currently does not exist in a clin-
ical workflow model.
Using the proposed framework, we can extract both standard (see Table 2) as well as
novel cMRI biomarkers [23-28] for diagnostic and prognostic purposes. An example of
a novel regional imaging biomarker that was recently discovered based on our analysis
of publicly available cMRIs within the Cardiac Atlas Project [29] databases, is briefly
discussed next. Cardiac MRIs of 25 symptomatic patients with coronary artery disease
or left ventricle impairment and 25 asymptomatic patients were used to extract
Table 2. Standard cMRI biomarkers produced by ReportCARD™ system (GE Healthcare)
Left Ventricle (LV)
Parameters
Right Ventricle (RV)
Parameters
Overall Cardiac
Parameters
A.S. Wall (cm)
P.S. Wall (cm)
End Diastolic Dimension (cm)
End Systolic Dimension (cm)
LV End Diastolic Vol (ml)
LV End Systolic Vol (ml)
LV Ejection Fraction (%)
LV End Diastolic Index (ml/m2)
LV End Systolic Index (ml/m2)
Fractional Shortening (%)
RV Major Axis (cm)
RV Minor Axis (cm)
RV End Diastolic Vol (ml)
RV End Systolic Vol (ml)
RV Major Axis Index (cm/m2)
RV Minor Axis Index (cm/m2)
RV Ejection Fraction (%)
RV End Diastolic Index (ml/m2)
RV End Systolic Index (ml/m2)
Stroke Volume (ml)
Stroke Volume Index (ml/m2)
Heart Rate (bpm)
Cardiac Output (l/min)
Cardiac Index (l/min/m2)
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cardiovascular function metrics. This also led to the discovery of a new regional ima-
ging biomarker of cardiac function that we call RMS-P2PD [23] which calculates the
root mean square (RMS) error from average phase to phase regional left ventricular
endocardial displacement, and is computed on a patient specific basis. In [23], we
depict how addition of this RMS-P2PD biomarker to standard biomarkers increased
the leave-one-out cross validation predictive accuracy of BRL models for ischemic car-
diomyopathy classification from 83.8% to 91.9%. The workflow depicted in Figure 1 is
aimed to augment the efficiency and accuracy with which clinical radiologists detect
and treat cardiovascular abnormalities in children.
Below we give an illustrative example for proof-of-concept of this framework, which
uses available rare data from the Children’s Hospital of Pittsburgh (CHP) of University
of Pittsburgh Medical Center (UPMC) which has a premier heart care program. The
framework can be used to assess whether or not certain types of cMRI biomarkers
measured using different technologies are suitable for classification of pediatric cardio-
myopathy, and if so, to what extent. An example would be to assess the value of strain
quantification measures from myocardial tagging sequence using cMRI to detect the
presence or absence of regional morphological changes as an early marker of cardio-
myopathy [15,16] in patients referred for cardiac imaging tests. Strain quantification is
a robust upcoming method for regional myocardial function evaluation, which explains
the underlying pathology of cardiomyopathy that can lead to timely management via
early intervention [16].
Dataset acquisition and characteristics: A de-identified retrospective cMRI dataset
was obtained as below under an ongoing IRB approved exempt study, by collecting
radiological images and electronic medical reports from the PACS and MARS servers
at the UPMC. Inclusion criteria consisted of patients seen at Children’s Hospital of
Pittsburgh between 1998 and 2014 who received a cardiac MRI to evaluate for cardio-
myopathy or myocarditis. Patients with incomplete or poor quality scans were
excluded. Measurements and biomarkers, including age, sex, height, weight, BSA, ven-
tricular volumes, masses and dimensions, wall thicknesses, myocardial delayed
enhancement, heart rate, and calculated measurements thereof were extracted from
the MRI reports (see Table 2 for list of standard cMRI biomarkers). The radiologist’s
impression was studied to determine what abnormality, if any, was present. In addition,
the most recent cardiology progress note, if present, was studied to determine the car-
diology diagnosis. If a patient had multiple cardiac MRIs, only the initial one was used.
This minimized the time between original presenting symptoms or concern for cardiac
anomaly and MRI. As a preliminary study, the dataset was filtered to eliminate patients
with conflicting MRI and cardiology diagnoses or uncertain diagnoses. The resulting
dataset included 83 patients age 0-22 (only four patients were between the ages of 19
and 22, with 2 males and 2 females, and equal distribution of one positive and one
negative case for each gender) evaluated with cMRI at CHP for cardiomyopathy or
myocarditis. For patients with multiple diagnoses (such as combined HCM and left
ventricular non compaction, LVNC), a judgment was made as to which one seemed to
be the primary diagnosis. Table 3 depicts the composition of the dataset including the
number of patients that received a negative diagnostic finding for cardiomyopathy, and
the number of patients that received a positive finding for a particular type of cardio-
myopathy. The dataset contained standard cMRI biomarkers (see Table 2) along with
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gender, age, diagnosis and myocardial delayed enhancement (MDE) status as a binary
variable. It is to be noted that a few of the markers in Table 2 such as Fractional
Shortening (FS), left and right ventricular ejection fractions, cardiac output and the
indices are derived parameters.
We constructed new variables based on the “normal” ranges for the left ventricular
(LV) and right ventricular (RV) end-systolic and end-diastolic volumes and Stroke
Volume parameters [30]. The parameters were normalized to the age and gender spe-
cific mean according to published control data [30] to determine whether a patient’s
volumes are within a normal range given his/her BSA. Patients with volumes that were
two standard deviations from the mean had parameters labelled as “low” or “high”,
with the remaining labelled as “normal”. Using this method, we created 5 new discrete
variables LVEDV Range, LVESV Range, RVEDV Range, RVESV Range and Stroke
Volume Range.
Image Acquisition and Processing: The cMRI images were acquired with a GE Sig-
naHDxt 1.5 Tesla MRI (GE Healthcare, WI, USA). Scans were performed by highly
experienced cardiac MRI technologists at CHP of UPMC. Due to their young ages, a
few patients who were unable to maintain breath hold for specific cMRI sequences
required general anesthesia during their MRI scans, as per their clinical protocols.
Cardiac sequences for function, flow and tissue characterization analyses require 15-20 sec
breath hold for image acquisition. A balanced steady state free precession sequence
(FIESTA, GE) was used in the short axis to acquire images for biventricular volumetric
analysis during 20 phases of the cardiac cycle. Relevant parameters included breath
holds = 1-2 (none for patients under general anesthesia), number of excitations = 1 for
patients with breath holds and 2 for patients under general anesthesia, repetition time =
3.6-4.0 ms, echo time = 1.5-1.7 ms, flip angle = 55°, slice thickness = 5-7 mm, and
acquisition matrix = 256 ± 256. Commercially available post-processing software Report-
CARDTM (GE Healthcare, WI, USA) was used to determine volumetric data, flow and
velocities.
Data Analysis Methods: The cMRI-derived biomarkers dataset containing 32 posi-
tive cases of cardiomyopathy/myocarditis and 51 negative controls and 30 predictor
variables containing no missing data was analyzed using our novel Bayesian Rule
Learning (BRL) methods [20,31]. BRL [20] works by searching for interactions between
predictors that are favorable for discriminating the target class values, which for this
dataset are represented by positive (Pos) or negative (Neg) MR diagnosis (MRDx). BRL
performs a heuristic, iterative search of the entire space of possible models represent-
ing interactions among potential predictors, and uses a Bayesian score [20] to represent
the uncertainty in the validity of each model based on the available training data. The
Table 3. Composition of patients in our retrospectively collected cMRI dataset
MR Diagnosis Total #patients (male, female)
HCM 9 (4, 5)
DCM 3 (1, 2)
ARVD 2 (2, 0)
LVNC 7 (4, 3)
Myocarditis 11 (9, 2)
Negative 51 (31, 20)
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greedy search starts with the highest scoring single predictor variable as the only par-
ent of the target class, and in each iteration adds the next highest scoring variable as
another parent to the target class and recalculates the Bayesian score [20]. The maxi-
mum number of parents or predictor variables of the target class is used to constrain
the model space (default value is 8). The BRL method in [20] was extended to handle
search of local structures in [31]. The Bayesian decision tree (BRL-DT) greedy search
of local structures within BRL allows for inclusion of different variables and varying
numbers of variables on the left hand side of related subsets of classification rules, as
long as this local variation produces an improvement in the Bayesian score for the
model (entire set of rules) [31]. This brief explanation is best understood by illustration
of the BRL-DT model in the results section below and its tree visualization depicted in
Figure 2.
BRL produces models that contain mutually exclusive and exhaustive classification
rules, so that only one rule applies for prediction on a test case. When using the BRL
system for developing and testing predictive models, we generally apply local structure
Figure 2 A portion of the Bayesian Decision Tree model from BRL is depicted to visualize the
classification rules. The predictor variables are shown in circles, and their values along each branch from
the root of the tree to the leaf node depicted as a rectangle, represents a classification rule within the
model. The rectangular leaf node represents the target variable, MRDx value for positive (Pos) or negative
(Neg) finding of cardiomyopathy. Four rules are shown with some associated statistics such as the
posterior probability (Prob) of the rule, and the numbers of true positives (TP) and false positives (FP)
covered by the rule. Two of the subtrees are not shown. From this tree, we can easily spot areas where
evidence is weak, strong, or could be combined. The variables shown include Myocardial Delayed
Enhancement (MDE), Right Ventricular End Systolic Volume Range (RVESVR), and the Right Ventricular
Ejection Fraction (RVEF%).
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search in addition to the original global structure search and present report results and
the model from the algorithm that performed the best over cross-validation.
Apart from BRL methods, we also applied three standard machine learning methods
available in the WEKA data mining environment [32]: Support Vector Machines
(SVMs) [33], C4.5 decision tree learning [34] and Random Forests (an ensemble
method) [35] to obtain 10-fold cross-validation performance using accuracy and area
under ROC curve (AUC) measures for this dataset.
Results
We present below a BRL decision tree [31] model to illustrate the kinds of interactions
between cMRI-derived markers that can be used for automatic classification. We used
a supervised discretization algorithm called Efficient Bayesian Discretization (EBD) [36]
available within BRL to discretize the continuous-valued input variables. EBD requires
a parameter called lambda, which is a prior that controls the total number of cut-
points from the desired discretization. We empirically varied this lambda parameter
between 0.5 and 4.0, in steps of 0.5 increments, and chose the lowest lambda value
that resulted in best cross-validation performance. For this dataset, we set the EBD
lambda parameter value to 3.5. The 10-fold cross validation accuracy we obtained on
this dataset was 80.72% with an AUC of 79.6%, which gave us confidence that reason-
ably accurate predictive models can be obtained from cMRI-derived biomarker data.
For illustrating this, we depict below the model from BRL that was obtained by learn-
ing on the entire training data (32 positives, 51 negatives). This model (see rules
below) was applied to the training data to make predictions, and fit the data with the
following statistics - Accuracy = 90.4%, Sensitivity = 78.13% and Specificity = 98.1% for
the Positive class, and an AUC value = 90.3%. The model used 6 variables: Myocardial
Delayed Enhancement (MDE), RV Ejection Fraction (RVEF%), LV End-Diastolic
Volume Range (LVEDVR), LV End-Systolic Volume Range (LVESVR), RV End-Systolic
Volume Range (RVESVR), and Stroke Volume Index (SVI ml/m2 ) as shown below
(Rules #1-8 classify Neg examples and rules # 9-13 classify Pos examples):
1. IF (MDE = No) & (RVESVR = Low) & (RVEF% = (33.7 to 57]) THEN (MRDx =
Neg)
Posterior Probability (Prob) = 0.857, P = 0.081, TP = 5, FP = 0
2. IF (MDE = No) & (RVESVR = Normal) & (LVEDVR = Normal) & (LVESVR =
Normal) & (SVI ml/m2 ≤ 67) THEN (MRDx = Neg)
Prob = 0.852, P = 0.001, TP = 22, FP = 3
3. IF (MDE = No) & (RVESVR = Normal) & (LVEDVR = Low) THEN (MRDx =
Neg)
Prob = 0.85, P = 0.005, TP = 16, FP = 2
4. IF (MDE = No) & (RVESVR = Normal) & (LVEDVR = Normal) & (LVESVR =
High) THEN (MRDx = Neg)
Prob = 0.8, P = 0.227, TP = 3, FP = 0
5. IF (MDE = No) & (RVESVR = Low) & (RVEF% > 57) & (LVEDVR = Normal)
THEN (MRDx = Neg)
Prob = 0.75, P = 0.375, TP = 2, FP = 0
6. IF (MDE = No) & (RVESVR = Low) & (RVEF% > 57) & (LVEDVR = Low) THEN
(MRDx = Neg)
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Prob = 0.5, P = 0.843, TP = 2, FP = 2
7. IF (MDE = No) & (RVESVR = Low) & (RVEF% ≤ 33.7) THEN (MRDx = Neg)
Prob = 0.5, P = 1.0, TP = 0, FP = 0
8. IF (MDE = No) & (RVESVR = Low) & (RVEF > 57) & (LVEDVR = High) THEN
(MRDx = Neg)
Prob = 0.5, P = 1.0, TP = 0, FP = 0
9. IF (MDE = Yes) THEN (MRDx = Pos)
Prob = 0.9, P = 0.0, TP = 17, FP = 1
10. IF (MDE = No) & (RVESVR = Normal) & (LVEDVR = Normal) & (LVESVR =
Low) THEN (MRDx = Pos) Prob = 0.8, P = 0.054, TP = 3, FP = 0
11. IF (MDE = No) & (RVESVR = Normal) & (LVEDVR = High) THEN (MRDx =
Pos)
Prob = 0.75, P = 0.146, TP = 2, FP = 0
12. IF (MDE = No) & (RVESVR = High) THEN (MRDx = Pos)
Prob = 0.75, P = 0.146, TP = 2, FP = 0
13. IF (MDE = No) & (RVESVR = Normal) & (LVEDVR = Normal) & (LVESVR =
Normal) & (SVI ml/m2 > 67) THEN (MRDx = Pos)
Prob = 0.667, P = 0.386, TP = 1, FP = 0
The posterior probability for each classification rule is calculated by BRL. In addition,
the rules also contain a p-value (P) that is calculated for each rule using Fisher’s exact
test. The number of true positives (TP) and false positives (FP) covered by each rule is
also reported. This model is depicted for purposes of illustration. From the above, we
notice at least a few general rules (# 2, 3 and 9) that are reasonable in terms of both
accuracy and coverage. The rules obtained from BRL are mutually exclusive and
exhaustive. It is interesting to note that two of the rules (#7 and 8) have no examples,
and depict areas wherein there is no evidence in the data. This implies that a diagnosis
of positive or negative for cardiomyopathy is equally likely given this training dataset.
However, the literature may have prior information that can be used to provide evi-
dence for one class over the other. For example, one of the features, namely right ven-
tricular ejection fraction /RVEF% ≤ 33.7 used in rule 7 is indicative of right heart
disease. By incorporating this as prior information into our Bayesian modeling frame-
work, we would be able to change the MRDx of the rule to positive class, rather than
the default majority class chosen as the diagnosis because of the lack of evidence
favouring a particular class.
These and others may also indicate the need to examine the discretization cutoff
ranges for discriminatory biomarkers, and also whether certain rules can be combined
together to improve overall model representation. The above classification rule model
is shown for illustrative purposes (see Figure 2 for a subset of the entire decision tree)
to depict how a parsimonious description of a complicated cardiac biomarker dataset
can be obtained using our BRL methods. The 6 variables selected by BRL are the vari-
ables that appear in the left hand side of the IF-THEN rules. They are extracted auto-
matically by the BRL system from the rule model. Because the rule model depicted is
obtained from local search of tree structures, the number of variables in each rule may
vary. With the original BRL global search method [20], each rule would have all the
variables, and the combination of values for the variables would vary for each rule so
as to cover all the possible combinations along the left-hand side of each mutually
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exclusive rule for the set of rules. In the local structure tree model, we obtain a more
parsimonious representation by this account.
Access to a larger training dataset will lead to more accurate classification rules and
in turn, better predictions on unseen test cases which can be used for validating our
models. While BRL was able to find rules that are established and well-known in the
literature [30], it must be noted that different discretization methods lead to different
cutoffs for the input variables. This issue must be addressed in order to enable stable
models to be learned from such cMRI datasets.
In order to ensure that the data that we have collected for our study is of sufficient
quality and to verify the classification performance of our method, we compared the
10-fold cross-validation accuracy and AUC measures of performance of the BRL deci-
sion tree to that of SVMs, C4.5 and Random Forests using the WEKA data mining
toolkit and its default parameter settings for each method. The BRL decision tree
method outperformed the other three classifiers as shown in Table 4. It is also clear
from the results that this rare dataset that we have collected is of good quality for clas-
sification of positive versus negative findings of pediatric cardiomyopathy as indicated
by the cross-validation performances from several popular machine learning methods
using just default parameter settings and no tuning.
Discussion
Preliminary results show the feasibility of our framework for processing such data
while also yielding actionable predictive classification rules that can augment knowl-
edge conveyed in cardiac radiology outcome reports. Interactions between MDE status
and other cMRI parameters that are depicted in our rules warrant further investigation
and validation. Predictive rules learned from cMRI data to classify positive and nega-
tive findings of cardiomyopathy can enhance scientific understanding of the underlying
interactions among imaging-derived parameters.
We are proposing a framework rather than a particular method, which means that
predictive modeling could be performed by other classification algorithms. We use
BRL for ease of interpretability of the predictive rules, and as shown in Table 4 and in
our previous studies it is comparable to or better than other popular classification
algorithms and extant rule learners [20,31]. We believe that our framework is flexible
enough to support (a) different predictive algorithms, and (b) novel biomarker discov-
ery. Both aspects require a human in the loop as indicated in Figure 1. We believe that
the main limitation of the methodology arises from the quality and quantities of data
available for doing the predictive modeling.
cMRI cardiomyopathy data is an example of a type of BIG data that presents several
informatics challenges. As seen in the results section, the collaborative efforts between
cardiac radiologists, data miners, biomedical engineers, technicians and biomedical
Table 4. Comparison of classifiers using 10-fold cross validation accuracy and AUC
Method Accuracy (%) AUC (%)
BRL-DT (EBD lambda = 3.5) 80.72 79.6
SVM (WEKA Linear kernel) 75.90 73.4
C4.5 (WEKA default settings) 78.31 73.9
Random Forests (WEKA default) 73.49 77.2
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informaticians will be crucial to establish and maintain databases or electronic reposi-
tories that can be used to create knowledge for transforming patient care. Based on
our experience in applying the cMRI-BED framework, we identify the following three
immediate informatics challenges that require elegant state-of-the-art solutions:
1. The need for a gold-standard, secure repository for storing the cardiac MR image
sequence specific manually traced contours and image annotations performed by Dr.
Madan on the entire sets of 2D, 3D and 4D images apart from the raw images
acquired and stored in DICOM formats for each (de-identified) patient in clinical set-
ting. Currently, these post-processed images are pushed to PACS for clinical reporting
following the post-processing at the dedicated cardiac workstation at CHP. Image
retrieval of post-processed images for clinical research is a cumbersome and deliberate
time exhausting task which affects the clinical research flow.
2. The need for adequately trained personnel to perform such annotations on exist-
ing CMR images. On an average, it takes at least one year to adequately train a tech-
nologist who has met prerequisites for performing clinical cardiac MRI procedure.
3. The need for a series of systematic studies that can provide adequate age, gender
and clinical history matched controls that are crucial for predictive modeling of cMRI
data.
Challenge #1 can be met by secure, cloud-based architectures that permit large data
storage and acquisition. Filling the second need (challenge #2) can enhance the pro-
ductivity of cardiac radiologists and improve clinical management. A single pediatric
radiologist reads and annotates about 350 cases in a year, because each case can take
anywhere from four to eight hours to capture cMRI data and process it to generate
and verify reports. Meeting challenge #3 will provide power to predictive modeling stu-
dies due to availability of matched case-controls in sufficient quantities to be able to
better understand and differentiate cardiac diseases. This will be necessary in order to
permit translation of this methodology into clinical practice. The cross-validation
accuracies and AUC performance measures reported in this paper, while promising,
are still not good enough for immediate clinical use in decision making. Future work
includes acquiring more data to enable accurate predictions that can used for clinical
decision-making, and subsequent automation of the cMRI-BED framework to eliminate
subjective bias to the extent possible.
Conclusions
Pediatric cardiomyopathies are significant diseases that are routinely examined using
cMRI. Pediatric cardiomyopathies are a heterogeneous group of serious disorders of
the myocardium and are responsible for significant morbidity and mortality among
children if not timely diagnosed. In this paper, we develop and test a novel workflow
called cMRI-BED for biomarker extraction and discovery from cMRI data. The novelty
arises from the iterative involvement and use of unique, predictive tools such as BRL
to model retrospectively available cMRI data and provide physicians with knowledge
that relates biomarker interactions to outcome classification. Moreover, the workflow
is flexible, scalable and largely independent of technology. Advances in cMRI technol-
ogy can lead to the development of new biomarkers, which can be easily incorporated
into our modeling framework. Retrospective data can be obtained from multiple insti-
tutions and summarization of these using BRL will help in drawing more general
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conclusions. Extensions to this workflow can also be made to allow for integration of
image biomarkers from multiple platforms using variants of extant algorithms for
transfer learning of classification rules [37].We believe that this cMRI-BED workflow
will help in the assessment of cMRI biomarkers in a timely fashion for improved diag-
nosis and prognosis of pediatric cardiomyopathies. The results from this feasibility
study suggest that our concept is broadly applicable to the study of any cardiovascular
disease using imaging-derived biomarkers, and will facilitate incorporation of computa-
tional thinking within complex clinical workflows.
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